"Mankind Pharma has launched its affordable generic version empagliflozin in India for diabetes following its patent expiration.
The launch follows patent expiration of empagliflozin sold by German drugmaker Boehringer Ingelheim under brand name Jardiance.
Mankind Pharma, India's fourth-largest firm by market share, said it will be selling a generic version of the drug Rs. 5.49 per tablet for the 10 mg variant and Rs. 9.9 per tablet for the 25 mg variant, making cheaper by more than 90%.
The cost of empagliflozin was earlier priced at Rs. 58.7 per tablet for the 10 mg dosage form and Rs. 71.1 for 25 mg.
“With this launch, Mankind Pharma has once again broken cost barriers by offering a product that combines international quality with affordability. By introducing empagliflozin at Rs. 5.49 per tablet for the 10 mg variant and Rs. 9.90 per tablet for the 25 mg variant, we are ensuring that cost is no longer a barrier to access. Aligned with our vision towards building a healthier Bharat, we remain committed in making high-quality medicines affordable and accessible to every patient in need. Our decision to deploy two separate teams to promote these offerings under distinct names ensures deeper market penetration and a broader reach in this highly competitive segment. Additionally, our extensive distribution network will ensure that this price innovation benefits patients in both urban and rural areas.”
Mankind Pharma offers a range of products under empagliflozin tablets which include Empaglyde, Empagreat and Dynaduo. Empaglyde tablets are available in strengths ranging from 10 mg to 25 mg. Empagreat tablets are also available in strengths ranging from 10 mg to 25. Dynaduo are available in strengths ranging from 10 mg to 25 mg.
Mankind has 9% anti-diabetic portfolio share in domestic sales. Mankind Pharma is dedicated to the development, manufacturing, and commercialization of a diverse range of pharmaceutical formulations. Its focus lies in addressing both acute and chronic therapeutic areas, with a strategic approach to introduce multiple brands within each therapeutic segment."